Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 21, 2015 3:00 PM ET

Pharmaceuticals

Company Overview of Cempra, Inc.

Company Overview

Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates include solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community acquired bacterial pneumonia, as well as for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has completed Phase II clinical trials for refractory bone and joint infections. The company also produces novel macrolides for non-antibiotic uses, such as the treatment of chronic inflammatory diseases, endocrine diseases, and gastric motility disorders. It has colla...

6320 Quadrangle Drive

Suite 360

Chapel Hill, NC 27517

United States

Founded in 2005

55 Employees

Phone:

919-313-6601

Key Executives for Cempra, Inc.

Founder, Chief Executive Officer, President and Director
Age: 65
Total Annual Compensation: $475.0K
Chief Financial Officer and Executive Vice President
Age: 51
Total Annual Compensation: $325.0K
Chief Commercialization Officer and Executive Vice President
Age: 40
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2014.

Cempra, Inc. Key Developments

Cempra, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Cempra, Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of $2,470,000 compared to revenues of $2,073,000 for the same period a year ago. Loss from operations was $16,264,000 compared to $16,148,000 last year. Net loss and comprehensive loss was $16,895,000 compared to $16,830,000 last year. Net loss attributable to common shareholders was $16,895,000 or $0.46 per basic and diluted share compared to $16,830,000 or $0.51 per basic and diluted share last year. Net loss has historically been driven largely by R&D spend, some of which is offset by revenue received under BARDA contract. For the year, the company reported revenues of $15,216,000 compared to revenues of $7,813,000 for the same period a year ago. Loss from operations was $59,400,000 compared to $42,920,000 last year. Net loss and comprehensive loss was $61,649,000 compared to $45,035,000 last year. Net loss attributable to common shareholders was $61,649,000 or $1.81 per basic and diluted share compared to $45,035,000 or $1.53 per basic and diluted share last year.

Cempra, Inc. to Report Q4, 2014 Results on Feb 25, 2015

Cempra, Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Feb 25, 2015

Cempra, Inc., Q4 2014 Earnings Call, Feb 25, 2015

Cempra, Inc., Q4 2014 Earnings Call, Feb 25, 2015

Similar Private Companies By Industry

Company Name Region
Warner Chilcott Holdings Company III, Limited United States
Damage Control Technologies, Inc. United States
Mastix Medica LLC United States
Ortek Therapeutics Inc. United States
Royal Health Care, Inc United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cempra, Inc., please visit www.cempra.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.